46 related articles for article (PubMed ID: 35345335)
1. KMT2C is a Potential Biomarker of Anti-PD-1 Treatment Response in Metastatic Melanoma.
Xie K; Peng Y; Zhong W; Liu X
Front Biosci (Landmark Ed); 2022 Mar; 27(3):103. PubMed ID: 35345335
[TBL] [Abstract][Full Text] [Related]
2. CD3ζ as a novel predictive biomarker of PD-1 inhibitor resistance in melanoma.
Zhang Z; Zhang D; Wang F; Liu J; Jiang X; Anuchapreeda S; Tima S; Xiao Z; Duangmano S
Mol Cell Probes; 2023 Dec; 72():101925. PubMed ID: 37567322
[TBL] [Abstract][Full Text] [Related]
3. KMT2C mutation as a predictor of immunotherapeutic efficacy in colorectal cancer.
Ni C; Wang X; Liu S; Zhang J; Luo Z; Xu B
Sci Rep; 2024 Apr; 14(1):8284. PubMed ID: 38594266
[TBL] [Abstract][Full Text] [Related]
4. Emerging biomarkers for cancer immunotherapy in melanoma.
Axelrod ML; Johnson DB; Balko JM
Semin Cancer Biol; 2018 Oct; 52(Pt 2):207-215. PubMed ID: 28917578
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of circular RNAs as novel putative biomarkers to predict anti-PD-1 monotherapy response in metastatic melanoma patients - Knowledge from two independent international studies.
Zhou JG; Liang R; Wang HT; Jin SH; Hu W; Frey B; Fietkau R; Hecht M; Ma H; Gaipl US
Neoplasia; 2023 Mar; 37():100877. PubMed ID: 36696838
[TBL] [Abstract][Full Text] [Related]
6. Functional Gene Expression Signatures from On-Treatment Tumor Specimens Predict Anti-PD1 Blockade Response in Metastatic Melanoma.
Chen S; Zhang L; Lin H; Liang Y; Wang Y
Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671443
[TBL] [Abstract][Full Text] [Related]
7. Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma.
Du K; Wei S; Wei Z; Frederick DT; Miao B; Moll T; Tian T; Sugarman E; Gabrilovich DI; Sullivan RJ; Liu L; Flaherty KT; Boland GM; Herlyn M; Zhang G
Nat Commun; 2021 Oct; 12(1):6023. PubMed ID: 34654806
[TBL] [Abstract][Full Text] [Related]
8. MTHFR act as a potential cancer biomarker in immune checkpoints blockades, heterogeneity, tumor microenvironment and immune infiltration.
Peng J; Wu Z
Discov Oncol; 2023 Jun; 14(1):112. PubMed ID: 37354330
[TBL] [Abstract][Full Text] [Related]
9. Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates.
Seyhan AA; Carini C
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613491
[TBL] [Abstract][Full Text] [Related]
10. Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy.
Zila N; Eichhoff OM; Steiner I; Mohr T; Bileck A; Cheng PF; Leitner A; Gillet L; Sajic T; Goetze S; Friedrich B; Bortel P; Strobl J; Reitermaier R; Hogan SA; Martínez Gómez JM; Staeger R; Tuchmann F; Peters S; Stary G; Kuttke M; Elbe-Bürger A; Hoeller C; Kunstfeld R; Weninger W; Wollscheid B; Dummer R; French LE; Gerner C; Aebersold R; Levesque MP; Paulitschke V
Clin Cancer Res; 2024 Jan; 30(1):159-175. PubMed ID: 37861398
[TBL] [Abstract][Full Text] [Related]
11. Nanometer-scale distribution of PD-1 in the melanoma tumor microenvironment.
Comerci CJ; McCarthy DG; Nosrati M; Kim KB; Kashani-Sabet M; Moerner WE; Leong SP
J Radiol Oncol; 2023; 7(1):20-25. PubMed ID: 37539093
[TBL] [Abstract][Full Text] [Related]
12. MLL3 loss drives metastasis by promoting a hybrid epithelial-mesenchymal transition state.
Cui J; Zhang C; Lee JE; Bartholdy BA; Yang D; Liu Y; Erler P; Galbo PM; Hodge DQ; Huangfu D; Zheng D; Ge K; Guo W
Nat Cell Biol; 2023 Jan; 25(1):145-158. PubMed ID: 36604594
[TBL] [Abstract][Full Text] [Related]
13. Association of KMT2C Genetic Variants with the Clinicopathologic Development of Oral Cancer.
Shieu MK; Ho HY; Lin SH; Lo YS; Lin CC; Chuang YC; Hsieh MJ; Chen MK
Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409657
[TBL] [Abstract][Full Text] [Related]
14. Mutations in epigenetic regulator
Zhu S; Xu N; Liang J; Zhao F; Wang Z; Ni Y; Dai J; Zhao J; Zhang X; Chen J; Sun G; Shen P; Zeng H
Oncol Res; 2023; 31(4):605-614. PubMed ID: 37415738
[TBL] [Abstract][Full Text] [Related]
15. KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis.
Limberger T; Schlederer M; Trachtová K; Garces de Los Fayos Alonso I; Yang J; Högler S; Sternberg C; Bystry V; Oppelt J; Tichý B; Schmeidl M; Kodajova P; Jäger A; Neubauer HA; Oberhuber M; Schmalzbauer BS; Pospisilova S; Dolznig H; Wadsak W; Culig Z; Turner SD; Egger G; Lagger S; Kenner L
Mol Cancer; 2022 Mar; 21(1):89. PubMed ID: 35354467
[TBL] [Abstract][Full Text] [Related]
16. Association of KMT2C/D loss-of-function variants with response to immune checkpoint blockades in colorectal cancer.
Liu R; Niu Y; Liu C; Zhang X; Zhang J; Shi M; Zou W; Gu B; Zhu H; Wang D; Yuan H; Li W; Zhao D; Zheng Q; Liu R; Chen W; Ma T; Zhang Y
Cancer Sci; 2023 Apr; 114(4):1229-1239. PubMed ID: 36601880
[TBL] [Abstract][Full Text] [Related]
17. CEBPB is associated with active tumor immune environment and favorable prognosis of metastatic skin cutaneous melanoma.
Yang J; Xu Y; Xie K; Gao L; Zhong W; Liu X
Front Immunol; 2022; 13():991797. PubMed ID: 36353635
[TBL] [Abstract][Full Text] [Related]
18. Mutations in a High-Grade Micropapillary Urothelial Carcinoma of the Renal Pelvis: A Case Report.
Uppaluri KR; Kambalachenu HR; Challa HJ; Raghuram Y S; Gadicherla R; Ketavath S; Palasamudram K; Sri Manjari K
Case Rep Oncol; 2023; 16(1):972-979. PubMed ID: 37900819
[TBL] [Abstract][Full Text] [Related]
19. The epigenetic modifier lysine methyltransferase 2C is frequently mutated in gastric remnant carcinoma.
Sun B; Chen H; Lao J; Tan C; Zhang Y; Shao Z; Xu D
J Pathol Clin Res; 2023 Sep; 9(5):409-422. PubMed ID: 37395342
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
